Amgen's $4B acquisition adds a newly approved drug; the last-minute push for drug pricing reform

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder By Adam Feuerstein Mark J. Terrill/AP The centerpiece of Amgen’s acquisition is a pill called Tavneos that treats patients with ANCA-associated vasculitis, an autoimmune disease Read More With monkeypox vaccine in high demand, NIH to test approaches to stretch supplies By Helen Branswell Jessica Christian/San Francisco Chronicle via AP The global need for monkeypox vaccine outstrips the supply, and will likely continue to do so for quite some time. Read More Listen: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble By Damian Garde and Allison DeAngelis and Adam Feuerstein Rachel Cohrs, STAT's Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing. Read More Sponsor content by STAT Events Biomarkers: The Foundation of Personalized Oncology Register for a virtual event on August 17 to hear researchers, academics, and business leaders discuss what recent innovations in biomarkers mean for the future of cancer treatments. Opinion: The outsized effect of 'modest' price controls on pharmaceutical innovation By Standish Fleming Adobe Industry advocates must explain how taking excess profits from pharma giants will affect startups, the real engine of pharma innovation. Read More New research digs into the genetic drivers of heart failure, with an eye to precision treatments By Elizabeth Cooney Adobe The study raises the possibility that some of the molecular pathways that lead to heart failure could be precisely targeted. Read More Thursday, August 4, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser